| Inflammatory bowel disease [IBD] and physical activity: a study on the impact of diagnosis on the level of exercise amongst patients with IBD K Gatt, J Schembri, KH Katsanos, D Christodoulou, K Karmiris, U Kopylov, ... Journal of Crohn's and Colitis 13 (6), 686-692, 2019 | 52 | 2019 |
| Endoscopic postoperative recurrence in Crohn’s disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world … H Yanai, A Kagramanova, O Knyazev, J Sabino, S Haenen, GJ Mantzaris, ... Journal of Crohn's and Colitis 16 (12), 1882-1892, 2022 | 30 | 2022 |
| Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab E Orfanoudaki, M Gazouli, K Foteinogiannopoulou, E Theodoraki, ... European Journal of Gastroenterology & Hepatology 31 (2), 187-191, 2019 | 13 | 2019 |
| Effectiveness of third-class biologic treatment in Crohn’s disease: a multi-center retrospective cohort study A Albshesh, J Taylor, EV Savarino, M Truyens, A Armuzzi, DG Ribaldone, ... Journal of clinical medicine 10 (13), 2914, 2021 | 12 | 2021 |
| Mental health, work presenteeism, and exercise in inflammatory bowel disease M Sciberras, K Karmiris, C Nascimento, T Tabone, P Nikolaou, ... Journal of Crohn's and Colitis 16 (8), 1197-1201, 2022 | 9 | 2022 |
| The burden and management of anemia in Greek patients with inflammatory bowel disease: A retrospective, multicenter, observational study K Foteinogiannopoulou, K Karmiris, G Axiaris, M Velegraki, A Gklavas, ... BMC gastroenterology 21, 1-10, 2021 | 9 | 2021 |
| Asymptomatic hyperCKemia during infliximab therapy in patients with inflammatory bowel disease E Theodoraki, E Orfanoudaki, K Foteinogiannopoulou, IE Koutroubakis Inflammatory Bowel Diseases 24 (6), 1266-1271, 2018 | 8 | 2018 |
| Use of vedolizumab in a patient with chronic and refractory pouchitis E Orfanoudaki, K Foteinogiannopoulou, IE Koutroubakis Annals of Gastroenterology 31 (3), 379, 2018 | 8 | 2018 |
| Solid extraintestinal malignancies in patients with inflammatory bowel disease A Mala, K Foteinogiannopoulou, IE Koutroubakis World Journal of Gastrointestinal Oncology 13 (12), 1956, 2021 | 7 | 2021 |
| Keeping on the high quality of health care in Greek inflammatory bowel disease patients in the SARS-CoV-2 era K Foteinogiannopoulou, E Orfanoudaki, IE Koutroubakis Clinical Gastroenterology and Hepatology 18 (10), 2380-2381, 2020 | 7 | 2020 |
| Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease? E Theodoraki, E Orfanoudaki, K Foteinogiannopoulou, E Legaki, ... Intestinal research 19 (4), 461, 2021 | 6 | 2021 |
| Gastroenteropancreatic neuroendocrine neoplasms in patients with inflammatory bowel disease: an ECCO CONFER multicentre case series S Festa, G Zerboni, LAAP Derikx, DG Ribaldone, G Dragoni, C Buskens, ... Journal of Crohn's and Colitis 16 (6), 940-945, 2022 | 5 | 2022 |
| First case of Whipple’s disease successfully treated with tigecycline K Foteinogiannopoulou, I Mouzas, M Tzardi, E Orfanoudaki, E Theodoraki, ... Germs 11 (1), 105, 2021 | 3 | 2021 |
| Recent advances in the optimization of anti-TNF treatment in patients with inflammatory bowel disease E Orfanoudaki, K Foteinogiannopoulou, E Theodoraki, IE Koutroubakis Journal of Clinical Medicine 12 (7), 2452, 2023 | 2 | 2023 |
| Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under … E Orfanoudaki, I Drygiannakis, E Theodoraki, K Foteinogiannopoulou, ... European Journal of Gastroenterology & Hepatology 33 (1S), e777-e782, 2021 | 2 | 2021 |
| Mucocutaneous manifestations in patients with inflammatory bowel disease: a decade study from a Greek cohort D Koumaki, A Machaira, AC Katoulis, P Bitados, E Orfanoudaki, ... European Journal of Gastroenterology & Hepatology 33 (11), 1387-1393, 2021 | 2 | 2021 |
| Active smoking is associated with the development of adverse events of biological therapy in patients with inflammatory bowel disease E Theodoraki, E Orfanoudaki, E Petroulaki, K Foteinogiannopoulou, ... European Journal of Gastroenterology & Hepatology 35 (1), 15-20, 2023 | 1 | 2023 |
| Infliximab trough levels are decreasing overtime in patients with inflammatory bowel disease on maintenance treatment with infliximab E Orfanoudaki, M Gazouli, K Foteinogiannopoulou, E Theodouraki, ... JOURNAL OF CROHNS & COLITIS 12, S330-S331, 2018 | 1 | 2018 |
| Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD S Vieujean, JO Lindsay, F D’Amico, V Ahuja, MS Silverberg, A Sood, ... Journal of Crohn's and Colitis 18 (4), 548-559, 2024 | | 2024 |
| Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study M Allocca, G Catalano, EV Savarino, M Chaparro, A Levartovsky, ... United European Gastroenterology Journal, 2024 | | 2024 |
Ioannis KoutroubakisMedical School, University of Crete, University Hospital HeraklionVerified email at med.uoc.gr
